Article

A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance.

Division of Medicine, Department of Hematology and Rheumatology, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
International journal of hematology (impact factor: 1.17). 02/2010; 91(3):530-3. DOI:10.1007/s12185-010-0511-2
Source: PubMed

ABSTRACT Although great advancements have been witnessed in treatment results for hematopoietic tumors in recent years, development of secondary malignant tumors induced by anti-cancer drugs still remains a serious issue. We experienced a case of secondary myelodysplastic syndrome (MDS), possibly induced by cyclophosphamide (CY), which was spontaneously resolved by discontinuance of CY. A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments. Remission was induced by rituximab, administered at the time of relapse in 2001, followed by administration of 50 mg/day of CY since December 2001 for the prevention of relapse. Anemia and thrombocytopenia developed around January 2003. Bone marrow aspiration revealed abnormality in two lineages and a complicated chromosomal anomaly, and the patient was diagnosed with MDS. Discontinuance of CY and administration of an anabolic steroid improved anemia and thrombocytopenia within 2 years. Bone marrow aspiration in 2006 showed improvement in morphological abnormality and disappearance of chromosomal abnormality.

0 0
 · 
0 Bookmarks
 · 
39 Views

Keywords

2 years
 
24-year-old woman
 
anabolic steroid
 
anti-cancer drugs
 
Bone marrow aspiration
 
bulky intra-abdominal lymphadenopathy
 
chemotherapy treatments
 
complicated chromosomal anomaly
 
CY
 
cyclophosphamide
 
great advancements
 
hematopoietic tumors
 
morphological abnormality
 
recent years
 
remission
 
secondary malignant tumors induced
 
secondary myelodysplastic syndrome
 
serious issue
 
thrombocytopenia
 
treatment results
 

Yoshiko Nakagawa